BACKGROUND: The combination antiretroviral therapy (cART) has dramatically improved the life expectancy of patients with HIV infection, but may lead to several long-term metabolic abnormalities. However, data about the frequency of metabolic syndrome (MS) in HIV-infected people vary considerably across different observational studies. METHODS: The prevalence of MS among HIV-infected patients was evaluated by a cross-sectional study conducted among subjects naive to cART or receiving the first antiretroviral regimen and referring to our Clinics from January 2015 to December 2015. The diagnosis of MS was made based on the National Cholesterol Education Program Adult Treatment Panel III (NCEP ATP III), and International Diabetes Federation (IDF) criteria. RESULTS: The study recruited 586 patients: 98 naive to cART and 488 under the first antiretroviral treatment. The prevalence of MS, according to NCEP-ATP III criteria, was significantly higher among treated patients than among naive ones (20.9% vs. 7.1%; p = 0.014). The most frequently reported components of MS among treated patients were high triglycerides (44.3%), low high-density lipoprotein cholesterol (41.1%), and hypertension (19.7%). On multivariate analysis, long duration of HIV infection, low nadir of CD4 lymphocytes, high body mass index, current use of one protease inhibitor, and long duration of cART were significantly associated with a higher risk of MS, while current use of one integrase inhibitor was significantly associated with a lower risk of MS. CONCLUSIONS: The non-negligible prevalence of MS among HIV-infected patients under cART requires a careful and periodic monitoring of its components, with particular attention to dyslipidemia and hypertension.
BACKGROUND: The combination antiretroviral therapy (cART) has dramatically improved the life expectancy of patients with HIV infection, but may lead to several long-term metabolic abnormalities. However, data about the frequency of metabolic syndrome (MS) in HIV-infectedpeople vary considerably across different observational studies. METHODS: The prevalence of MS among HIV-infectedpatients was evaluated by a cross-sectional study conducted among subjects naive to cART or receiving the first antiretroviral regimen and referring to our Clinics from January 2015 to December 2015. The diagnosis of MS was made based on the National Cholesterol Education Program Adult Treatment Panel III (NCEP ATP III), and International Diabetes Federation (IDF) criteria. RESULTS: The study recruited 586 patients: 98 naive to cART and 488 under the first antiretroviral treatment. The prevalence of MS, according to NCEP-ATP III criteria, was significantly higher among treated patients than among naive ones (20.9% vs. 7.1%; p = 0.014). The most frequently reported components of MS among treated patients were high triglycerides (44.3%), low high-density lipoprotein cholesterol (41.1%), and hypertension (19.7%). On multivariate analysis, long duration of HIV infection, low nadir of CD4 lymphocytes, high body mass index, current use of one protease inhibitor, and long duration of cART were significantly associated with a higher risk of MS, while current use of one integrase inhibitor was significantly associated with a lower risk of MS. CONCLUSIONS: The non-negligible prevalence of MS among HIV-infectedpatients under cART requires a careful and periodic monitoring of its components, with particular attention to dyslipidemia and hypertension.
Authors: Hann Low; Anh Hoang; Tatiana Pushkarsky; Larisa Dubrovsky; Elizabeth Dewar; Maria-Silvana Di Yacovo; Nigora Mukhamedova; Lesley Cheng; Catherine Downs; Gary Simon; Maria Saumoy; Andrew F Hill; Michael L Fitzgerald; Paul Nestel; Anthony Dart; Jennifer Hoy; Michael Bukrinsky; Dmitri Sviridov Journal: PLoS One Date: 2019-04-18 Impact factor: 3.240
Authors: Catalina Barceló; Monia Guidi; Christian W Thorball; Christian Hammer; Aziz Chaouch; Alexandra U Scherrer; Barbara Hasse; Matthias Cavassini; Hansjakob Furrer; Alexandra Calmy; Sebastian Haubitz; Enos Bernasconi; Thierry Buclin; Jacques Fellay; Philip E Tarr; Chantal Csajka Journal: Open Forum Infect Dis Date: 2020-01-22 Impact factor: 4.423
Authors: Sepiso K Masenga; Fernando Elijovich; John R Koethe; Benson M Hamooya; Douglas C Heimburger; Sody M Munsaka; Cheryl L Laffer; Annet Kirabo Journal: Curr Hypertens Rep Date: 2020-09-03 Impact factor: 5.369
Authors: Prasanta K Dash; Fadhel A Alomar; Jesse L Cox; JoEllyn McMillan; Bryan T Hackfort; Edward Makarov; Brenda Morsey; Howard S Fox; Howard E Gendelman; Santhi Gorantla; Keshore R Bidasee Journal: Front Cardiovasc Med Date: 2021-12-14